Relevant Gene Module for Childhood-Onset Asthma
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
ABSTRACT ANGSTADT, ANDREA Y. Evaluation of the Genomic
ABSTRACT ANGSTADT, ANDREA Y. Evaluation of the Genomic Aberrations in Canine Osteosarcoma and Their Resemblance to the Human Counterpart. (Under the direction of Dr. Matthew Breen). In the last decade the domestic dog has emerged as an ideal biomedical model of complex genetic diseases such as cancers. Cancer in the dog occurs spontaneously and several studies have concluded that human and canine cancers have similar characteristics such as presentation of disease, rate of metastases, genetic dysregulation, and survival rates. Furthermore, in the genomic era the dog genome was found more homologous in sequence conservation to humans than mice, making it a valuable model organism for genetic study in addition to pathophysiological analysis. Osteosarcoma (OS), the most commonly diagnosed malignant bone tumor in humans and dogs, is one such cancer that would benefit from comparative genomic analysis. In humans, OS is a rare cancer diagnosed in fewer than 1,000 people per year in the USA, while in the domestic dog population the annual number of new cases is estimated to far exceed 10,000. This high rate of disease occurrence in dogs provides a unique opportunity to study the genomic imbalances in canine OS and their translational value to human OS as a means to identify important alterations involved in disease etiology. OS in humans is characterized by extremely complex karyotypes which contain both structural changes (translocations and/or rearrangements) and DNA copy number changes. Metaphase and array comparative genomic hybridization (aCGH) has assisted in uncovering the genetic imbalances that are associated with human OS phenotype. In dog OS, previous low-resolution (10-20Mb) aCGH analysis identified a wide range of recurrent copy number aberrations (CNAs), indicative of a similar level of genomic instability to human OS. -
PRODUCT SPECIFICATION Anti-C12orf43
Anti-C12orf43 Product Datasheet Polyclonal Antibody PRODUCT SPECIFICATION Product Name Anti-C12orf43 Product Number HPA046148 Gene Description chromosome 12 open reading frame 43 Clonality Polyclonal Isotype IgG Host Rabbit Antigen Sequence Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: AWGLEQRPHVAGKPRAGAANSQLSTSQPSLRHKVNEHEQDGNELQTTPEF RAHVAKKLGALLDSFITISEAAKEPAKAKVQKVALEDDGFRLFFTSVPGG REKEESPQPR Purification Method Affinity purified using the PrEST antigen as affinity ligand Verified Species Human Reactivity Recommended IHC (Immunohistochemistry) Applications - Antibody dilution: 1:50 - 1:200 - Retrieval method: HIER pH6 WB (Western Blot) - Working concentration: 0.04-0.4 µg/ml ICC-IF (Immunofluorescence) - Fixation/Permeabilization: PFA/Triton X-100 - Working concentration: 0.25-2 µg/ml Characterization Data Available at atlasantibodies.com/products/HPA046148 Buffer 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative. Concentration Lot dependent Storage Store at +4°C for short term storage. Long time storage is recommended at -20°C. Notes Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user. For protocols, additional product information, such as images and references, see atlasantibodies.com. Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB. Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
In This Issue
THE JOURNAL OF IMMUNOLOGY IN THIS ISSUE Limiting C damage rather than decreased proliferation after recruitment by measur- ing infiltrating donor cells 6 h after injection. CXCR6 defi- ϩ reventing the forma- ciency did not alter levels of donor CD8 T cells in the blood or tion of the C3 conver- spleen compared with wild-type donor cells. The data support a ϩ P tase reduces damage specific role for CXCR6 in homing of activated donor CD8 T from inflammation following cells to the inflamed liver in graft-vs-host-induced hepatitis. activation of the mammalian C classical pathway. Schisto- soma complement C2 receptor inhibitor trispanning (CRIT) TLR enhancement of diabetes is known to bind C2 and pre- vent its cleavage. Inal et al. (p. 356) found CRIT homologues in ilham rat virus (KRV) infection of BBDR rats results genomic DNA from Trypanosoma, human, rat, and cod by in type 1 diabetes in ϳ25% of the animals. The fre- Southern blotting and PCR. Ab against an extracellular N- K quency is increased to 100% in rats pretreated with terminal peptide enabled detection of CRIT on the surface of the TLR3 agonist poly(I:C). To investigate the role of TLR- Jurkat cells by flow cytometry. CRIT expression in a wide range induced activation of innate immunity in autoimmune diabetes of human tissues and cells was shown using Abs against the induction, Zipris et al. (p. 131) found that pretreatment of N-terminal peptide and other regions of the protein. The bind- BBDR rats with other TLR ligands, including heat-killed bac- ing of biotinylated C2 to filter-immobilized CRIT or of fluo- teria, also enhanced KRV-induced diabetes induction; some li- rescence-labeled C2 to Jurkat cells was abolished by preincuba- gands were effective at low viral doses that were not usually di- tion of the filter or cells with anti-N-terminal peptide Ab; abetogenic. -
G Protein-Coupled Receptors As Therapeutic Targets for Multiple Sclerosis
npg GPCRs as therapeutic targets for MS Cell Research (2012) 22:1108-1128. 1108 © 2012 IBCB, SIBS, CAS All rights reserved 1001-0602/12 $ 32.00 npg REVIEW www.nature.com/cr G protein-coupled receptors as therapeutic targets for multiple sclerosis Changsheng Du1, Xin Xie1, 2 1Laboratory of Receptor-Based BioMedicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sci- ences and Technology, Tongji University, Shanghai 200092, China; 2State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Pudong New District, Shanghai 201203, China G protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmit- ters and environmental stimulants. They are considered as the most successful therapeutic targets for a broad spec- trum of diseases. Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated de- myelination and degeneration of the central nervous system (CNS). It is the leading cause of non-traumatic disability in young adults. Great progress has been made over the past few decades in understanding the pathogenesis of MS. Numerous data from animal and clinical studies indicate that many GPCRs are critically involved in various aspects of MS pathogenesis, including antigen presentation, cytokine production, T-cell differentiation, T-cell proliferation, T-cell invasion, etc. In this review, we summarize the recent findings regarding the expression or functional changes of GPCRs in MS patients or animal models, and the influences of GPCRs on disease severity upon genetic or phar- macological manipulations. -
Download Download
Supplementary Figure S1. Results of flow cytometry analysis, performed to estimate CD34 positivity, after immunomagnetic separation in two different experiments. As monoclonal antibody for labeling the sample, the fluorescein isothiocyanate (FITC)- conjugated mouse anti-human CD34 MoAb (Mylteni) was used. Briefly, cell samples were incubated in the presence of the indicated MoAbs, at the proper dilution, in PBS containing 5% FCS and 1% Fc receptor (FcR) blocking reagent (Miltenyi) for 30 min at 4 C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL (Coulter Electronics Inc., Hialeah, FL, USA) flow cytometer. only use Non-commercial 1 Supplementary Table S1. Complete list of the datasets used in this study and their sources. GEO Total samples Geo selected GEO accession of used Platform Reference series in series samples samples GSM142565 GSM142566 GSM142567 GSM142568 GSE6146 HG-U133A 14 8 - GSM142569 GSM142571 GSM142572 GSM142574 GSM51391 GSM51392 GSE2666 HG-U133A 36 4 1 GSM51393 GSM51394 only GSM321583 GSE12803 HG-U133A 20 3 GSM321584 2 GSM321585 use Promyelocytes_1 Promyelocytes_2 Promyelocytes_3 Promyelocytes_4 HG-U133A 8 8 3 GSE64282 Promyelocytes_5 Promyelocytes_6 Promyelocytes_7 Promyelocytes_8 Non-commercial 2 Supplementary Table S2. Chromosomal regions up-regulated in CD34+ samples as identified by the LAP procedure with the two-class statistics coded in the PREDA R package and an FDR threshold of 0.5. Functional enrichment analysis has been performed using DAVID (http://david.abcc.ncifcrf.gov/) -
Dampening Cytokine Production HIV Susceptibility Locus Targeting
RESEARCH HIGHLIGHTS Dampening cytokine production circulating pDCs uniquely express a chemokine receptor known as che- mokine-like receptor 1 (CMKLR1, also known as ChmeR23 or DEZ) that Although TRAIL receptor (TRAIL-R) signaling is associated with distinguishes them from mDCs. The ligand for CMKLR1, chemerin, was apoptosis induction in vitro, the in vivo function of TRAIL-R is not detectable in human sera. The mRNA of chemerin was also present in well understood. In Immunity, Winoto and colleagues show that the many tissues, including the liver, pancreas and adrenal glands. Chemerin innate immune response to certain pathogens is enhanced in TRAIL- attracted blood pDCs but not mDCs. Because active chemerin requires R-deficient mice. Increased clearance of mouse cytomegalovirus proteolytic processing, the presence of these enzymes at sites of inflam- from the spleen was associated with increased IL-12, IFN-α and mation and tissue damage may serve to recruit pDCs. PTL IFN-β production by dendritic cells and macrophages. Likewise, J. Immunol. 174, 244–251 (2005) Toll-like receptor 2 (TLR2), TLR3 and TLR4 stimulation, along with mycobacterial stimulation, enhanced cytokine production and also induced upregulation of TRAIL expression by these innate immune HIV susceptibility locus cells. Specifically, TRAIL-R deficiency affected re-expression of IκBα at later times after TLR signaling. These data show TRAIL-R The CC chemokine CCL31L, also called MIP-1αP, has a signaling normally negatively regulates the cytokine response of the suppressive function in HIV infection. CCL31L is the main ligand innate immune system. JDKW for the HIV co-receptor CCR5. In Science, Gonzalez et al. -
Anti-Mouse CMKLR1 PE Catalog Number: 12‐7582 Also Known As:Serpentine Chemokine‐Like Receptor 1 RUO: for Research Use Only
Anti-Mouse CMKLR1 PE Catalog Number: 12‐7582 Also Known As:serpentine chemokine‐like receptor 1 RUO: For Research Use Only Staining of resident mouse peritoneal macrophages with 0.25 µg of Rat IgG2a κ Isotype Control PE (cat. 12‐4321) (open histogram) or 0.25 µg of Anti‐Mouse CMKLR1 PE (filled histogram). Cells in the large scatter population (CD11b positive) were used for analysis. Product Information Contents: Anti‐Mouse CMKLR1 PE Formulation: aqueous buffer, 0.09% sodium azide, may contain Catalog Number: 12‐7582 carrier protein/stabilizer Clone: BZ194 (194) Temperature Limitation: Store at 2‐8°C. Do not freeze. Light Concentration: 0.2 mg/ml sensitive material. Host/Isotype: Rat IgG2a, κ Batch Code: Refer to Vial Use By: Refer to Vial Caution, contains Azide Description The 194.7.4 (BZ194)monoclonal antibody reacts to mouse Chemoattractant‐like receptor 1 (CMKLR1), also known as ChemR23 and DEZ. CMKLR1 is the receptor for chemerin, a potent chemoattractant. The BZ194 antibody was generated against the amino terminal residues of mouse CMKLR1. In the human CMKLR is found on pDC while in the mouse expression is confined to resident peritoneal macrophages with highest expression on Cd11blo macrophages. Expression is absent on in vitro cultured bone marrow DCs (except on early DCs as defined by CD11c+MHCIIint), and on freshly isolated CD11c+ cells from lymph node, spleen and bone marrow. Mouse CMKLR is thought to play a role in macrophage function as a result of injury. Applications Reported This BZ194 (194) antibody has been reported for use in flow cytometric analysis. -
The Atypical Receptor Ccrl2 (C-C Chemokine Receptor-Like 2) Does Not Act As a Decoy Receptor in Endothelial Cells
ORIGINAL RESEARCH published: 06 October 2017 doi: 10.3389/fimmu.2017.01233 The Atypical Receptor CCRL2 (C-C Chemokine Receptor-Like 2) Does Not Act As a Decoy Receptor in Endothelial Cells Chiara Mazzotti1, Vincenzo Gagliostro1, Daniela Bosisio1, Annalisa Del Prete1,2, Laura Tiberio1, Marcus Thelen 3 and Silvano Sozzani1,2* 1 Laboratory of Experimental Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, 2 Humanitas Clinical and Research Centre, Rozzano, Italy, 3 Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland C-C chemokine receptor-like 2 (CCRL2) is a non-signaling seven-transmembrane domain (7-TMD) receptor related to the atypical chemokine receptor (ACKR) family. ACKRs bind chemokines but do not activate G protein-dependent signaling or cell functions. ACKRs were shown to regulate immune functions in vivo by their ability Edited by: to scavenge chemokines from the local environment. This study was performed to Ji Ming Wang, National Cancer Institute investigate whether CCRL2 shares two of the main characteristics of ACKRs, namely at Frederick, United States the ability to internalize and scavenge the ligands. Cell membrane analysis of CCRL2- Reviewed by: transfected cells revealed a weak, constitutive, ligand-independent internalization, and Santos Mañes, recycling of CCRL2, with a kinetics that was slower than those observed with ACKR3, Consejo Superior de Investigaciones Científicas a prototypic ACKR, or other chemotactic signaling receptors [i.e., chemokine-like (CSIC), Spain receptor 1 and C-X-C motif chemokine receptor 2]. Intracellularly, CCRL2 colocalized Diana Boraschi, Consiglio Nazionale with early endosome antigen 1-positive and Rab5-positive vesicles and with recycling Delle Ricerche (CNR), Italy compartments mainly characterized by Rab11-positive vesicles. -
Adipose Recruitment and Activation of Plasmacytoid Dendritic Cells Fuel Metaflammation’
Diabetes Page 2 of 61 Adipose recruitment and activation of plasmacytoid dendritic cells fuel metaflammation Amrit Raj Ghosh1, Roopkatha Bhattacharya1, Shamik Bhattacharya1, Titli Nargis2, Oindrila Rahaman1, Pritam Duttagupta1, Deblina Raychaudhuri1, Chinky Shiu Chen Liu1, Shounak Roy1, Parasar Ghosh3, Shashi Khanna4, Tamonas Chaudhuri4, Om Tantia4, Stefan Haak5, Santu Bandyopadhyay1, Satinath Mukhopadhyay6, Partha Chakrabarti2 and Dipyaman Ganguly1*. Divisions of 1Cancer Biology & Inflammatory Disorders and 2Cell Biology & Physiology, CSIR- Indian Institute of Chemical Biology, Kolkata, India; 4ILS Hospitals, Kolkata, India; 5Zentrum Allergie & Umwelt (ZAUM), Technical University of Munich and Helmholtz Centre Munich, Munich, Germany; Departments of 3Rheumatology and 6Endocrinology, Institute of Postgraduate Medical Education & Research, Kolkata, India. *Corresponding author: Dipyaman Ganguly, Division of Cancer Biology & Inflammatory Disorders, CSIR-Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Jadavpur, Kolkata, West Bengal, India, 700032. Phone: 91 33 24730492 Fax: 91 33 2473 5197 Email: [email protected] Running title: PDCs and type I interferons in metaflammation Word count (Main text): 5521 Figures: 7, Table: 1 1 Diabetes Publish Ahead of Print, published online August 25, 2016 Page 3 of 61 Diabetes ABSTRACT In obese individuals the visceral adipose tissue (VAT) becomes seat of chronic low grade inflammation (metaflammation). But the mechanistic link between increased adiposity and metaflammation remains largely -
The Genetic Regulation of Size Variation in the Transcriptome of The
Höglund et al. BMC Genomics (2020) 21:518 https://doi.org/10.1186/s12864-020-06908-0 RESEARCH ARTICLE Open Access The genetic regulation of size variation in the transcriptome of the cerebrum in the chicken and its role in domestication and brain size evolution Andrey Höglund1, Katharina Strempfl1,2,3, Jesper Fogelholm1, Dominic Wright1† and Rie Henriksen1*† Abstract Background: Large difference in cerebrum size exist between avian species and populations of the same species and is believed to reflect differences in processing power, i.e. in the speed and efficiency of processing information in this brain region. During domestication chickens developed a larger cerebrum compared to their wild progenitor, the Red jungle fowl. The underlying mechanisms that control cerebrum size and the extent to which genetic regulation is similar across brain regions is not well understood. In this study, we combine measurement of cerebrum size with genome-wide genetical genomics analysis to identify the genetic architecture of the cerebrum, as well as compare the regulation of gene expression in this brain region with gene expression in other regions of the brain (the hypothalamus) and somatic tissue (liver). Results: We identify one candidate gene that putatively regulates cerebrum size (MTF2) as well as a large number of eQTL that regulate the transcriptome in cerebrum tissue, with the majority of these eQTL being trans-acting. The overall regulation of gene expression variation in the cerebrum was markedly different to the hypothalamus, with relatively few eQTL in common. In comparison, the cerebrum tissue shared more eQTL with a distant tissue (liver) than with a neighboring tissue (hypothalamus). -
Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - a Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort
Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - A Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort Karina Standahl Olsen1*, Christopher Fenton2, Livar Frøyland3, Marit Waaseth4, Ruth H. Paulssen2, Eiliv Lund1 1 Department of Community Medicine, University of Tromsø, Tromsø, Norway, 2 Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, 3 National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway, 4 Department of Pharmacy, University of Tromsø, Tromsø, Norway Abstract High blood concentrations of n-6 fatty acids (FAs) relative to n-3 FAs may lead to a ‘‘physiological switch’’ towards permanent low-grade inflammation, potentially influencing the onset of cardiovascular and inflammatory diseases, as well as cancer. To explore the potential effects of FA ratios prior to disease onset, we measured blood gene expression profiles and plasma FA ratios (linoleic acid/alpha-linolenic acid, LA/ALA; arachidonic acid/eicosapentaenoic acid, AA/EPA; and total n-6/n-3) in a cross-section of middle-aged Norwegian women (n = 227). After arranging samples from the highest values to the lowest for all three FA ratios (LA/ALA, AA/EPA and total n-6/n-3), the highest and lowest deciles of samples were compared. Differences in gene expression profiles were assessed by single-gene and pathway-level analyses. The LA/ALA ratio had the largest impact on gene expression profiles, with 135 differentially expressed genes, followed by the total n-6/ n-3 ratio (125 genes) and the AA/EPA ratio (72 genes). All FA ratios were associated with genes related to immune processes, with a tendency for increased pro-inflammatory signaling in the highest FA ratio deciles.